DMAC vs. COYA, VTGN, NVCT, FGEN, ADAG, IMUX, AMLX, ABEO, OPTN, and RZLT
Should you be buying DiaMedica Therapeutics stock or one of its competitors? The main competitors of DiaMedica Therapeutics include Coya Therapeutics (COYA), Vistagen Therapeutics (VTGN), Nuvectis Pharma (NVCT), FibroGen (FGEN), Adagene (ADAG), Immunic (IMUX), Amylyx Pharmaceuticals (AMLX), Abeona Therapeutics (ABEO), OptiNose (OPTN), and Rezolute (RZLT). These companies are all part of the "pharmaceutical preparations" industry.
Coya Therapeutics (NASDAQ:COYA) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, community ranking, risk, analyst recommendations, institutional ownership, valuation and earnings.
39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are held by institutional investors. 9.8% of Coya Therapeutics shares are held by insiders. Comparatively, 7.2% of DiaMedica Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Coya Therapeutics had 4 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 9 mentions for Coya Therapeutics and 5 mentions for DiaMedica Therapeutics. Coya Therapeutics' average media sentiment score of 1.12 beat DiaMedica Therapeutics' score of 0.25 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media.
Coya Therapeutics' return on equity of -36.21% beat DiaMedica Therapeutics' return on equity.
Coya Therapeutics has higher revenue and earnings than DiaMedica Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks.
Coya Therapeutics has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500.
DiaMedica Therapeutics received 82 more outperform votes than Coya Therapeutics when rated by MarketBeat users. However, 88.89% of users gave Coya Therapeutics an outperform vote while only 62.07% of users gave DiaMedica Therapeutics an outperform vote.
Coya Therapeutics presently has a consensus target price of $14.00, indicating a potential upside of 66.67%. DiaMedica Therapeutics has a consensus target price of $7.00, indicating a potential upside of 132.56%. Given Coya Therapeutics' higher probable upside, analysts clearly believe DiaMedica Therapeutics is more favorable than Coya Therapeutics.
Summary
DiaMedica Therapeutics beats Coya Therapeutics on 8 of the 14 factors compared between the two stocks.
Get DiaMedica Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DiaMedica Therapeutics Competitors List
Related Companies and Tools
